What do systematic reviews say?

Virtual reality vs active intervention (short term)

• Virtual reality for rehabilitation in Parkinson's disease 2016 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 106 participants
  Very low

Tiotropium vs ipratropium

• Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 535 participants
  Moderate

Intervention not reported

• The effect of pharmacist‐provided non‐dispensing services on patient outcomes, health service utilisation and costs in… 2013 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 777 participants
  Moderate

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs macular laser

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal steroid

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: intravitreal bevacizumab plus intravitreal steroid vs intravitreal anti‐VEGF

The review found no eligible studies for this question.

• Anti‐vascular endothelial growth factor combined with intravitreal steroids for diabetic macular oedema 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

SUPPORTIVE THERAPY vs ANY OTHER PSYCHOLOGICAL OR PSYCHOSOCIAL TREATMENT

• Supportive therapy for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

SUPPORTIVE THERAPY vs PSYCHOEDUCATION

• Supportive therapy for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 19 participants
  Very low

SUPPORTIVE THERAPY vs usual care

• Supportive therapy for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 260 participants
  Very low

SOCIAL SKILLS vs DISCUSSION CONTROL

• Social skills programmes for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 63 participants
  Very low

COMPARISON 1. ARIPIPRAZOLE vs OLANZAPINE

• Aripiprazole versus other atypical antipsychotics for schizophrenia 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 68 participants
  Very low

Mental practice in addition to other treatment vs other treatment (± placebo)

• Mental practice for treating upper extremity deficits in individuals with hemiparesis after stroke 2020 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Biological therapy vs placebo, best supportive care (BSC) or no treatment

• Salvage systemic therapy for advanced gastric and oesophago‐gastric junction adenocarcinoma 2020 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 283 participants
  Low

SUPPORTIVE THERAPY vs cognitive behavioural therapy

• Supportive therapy for schizophrenia 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 65 participants
  Very low

Summary of findings 1: PLD with chemotherapy vs alternative combination chemotherapy

• Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 608 participants
  Low

Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI maintenance vs chemotherapy alone

The review found no eligible studies for this question.

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 486 participants
  Low

Chemotherapy with TKI followed by TKI maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 146 participants
  Low

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 890 participants
  High

Chemotherapy with TKI vs chemotherapy alone

Chemotherapy with TKI showed no clear difference in quality of life (QoL) compared with chemotherapy alone (low certainty).

• Angiogenesis inhibitors for the treatment of epithelial ovarian cancer 2023 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 164 participants
  Low